SkylineDx

SkylineDx is a biotech company specializing in molecular diagnostics for oncology and inflammatory diseases. The company uses its diagnostics to connect gene expression that enables healthcare providers to  identify the type of a disease, predict a patient's response to treatment, and provide personalized treatment plans for each patient. 

SkylineDx's lead product is MMprofiler with SKY92, a clinical test that measures the activity of 92 cancer genes and is used to aid physicians in the prognosis of multiple myeloma (blood cancer). The company claims it offers the most reliable test for predicting a patient's condition. The test is available as a CE-IVD kit in Europe and as a CLIA validated Laboratory Developed Test (LDT) in the US. The company also has a R&D program called “Falcon” that aims to develop an array of diagnostic utilities for melanoma patients, providing physicians with the tools to optimize the clinical pathway of their patients. 

In addition to its commercialized product, the company has a pipeline of products to expand its genetic-based diagnostic tests for cancer (developed under the Peregrine Study Initiative) and inflammatory diseases. Furthermore, the company has several undisclosed biomarker discovery projects under its Strix Biomarker Discovery Services.  

Key Customers and Partnerships

The company has several key partnerships including with BioInvent International AB (March 2020) to characterize gene expression and immunological signatures in tumors of patients pre- and post-treatment with BioInvent’s lead candidate BI-1206, Imperial College London and University of California San Diego (September 2020) to develop a diagnostic test for early diagnosis of Kawasaki disease (an inflammatory disease affecting infants and young children), VIB (in December 2021) for a three-year strategic partnership to collaborate on molecular diagnostics projects, and German lab developer NeraCare (in April 2023) to co-develop a proteomic test called “Immunoprint” for survival prediction of melanoma patients.

Funding and Financials

The company raised an undisclosed amount in December 2021 from Novalis LifeSciences and Van Herk Investments. The funds raised were used toward expanding its US market.